Clincosm LogoSign in Get a demo

ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure

Sponsor
Zealand Pharma (Industry)
Overall Status
Terminated
CT.gov ID
NCT00283361
Collaborator
Syneos Health (Other)
130
Enrollment
22
Locations
11
Duration (Months)
5.9
Patients Per Site
0.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The main purpose of this study is to see if the experimental drug ZP120, when given with the approved drug furosemide to patients with acute or sub-acute heart failure, can reduce the amount of fluid in the patients' lungs and make breathing easier.

Condition or Disease Intervention/Treatment Phase
  • Drug: ZP120
  • Procedure: I.v. catherization
  • Procedure: 6-minutes walk performance
  • Behavioral: Dyspnea severity assessment
  • Procedure: Blood sampling for laboratory tests
  • Procedure: ECG
  • Procedure: Physical examination
 Phase 2

Study Design

Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Official Title:
A Phase II,Randomized, Double-Blind, Flexible Dose Study of ZP120 I.V. Infusion as Add-On Therapy in Patients With Acute or Sub-Acute Decompensated Chronic Heart Failure NYHA Class III-IV Treated With Furosemide
Study Start Date :
Jan 1, 2006
Study Completion Date :
Dec 1, 2006

Outcome Measures

Primary Outcome Measures

  1. Change in dyspnea severity []

Secondary Outcome Measures

  1. Change in 6-minute walk test performance []

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  1. Male or female patients, age 18 years or more

  2. A diagnosis of acute or subacute decompensated chronic heart failure, either ischemic or nonischemic, requiring hospitalization, and currently treated with furosemide, torsemide, or bumetadine, and other evidence based optimal treatment for heart failure. Patients must have the clinical diagnosis of CHF made at least 3 month prior to enrollment

  3. Ambulatory

  4. Objective signs of LVD corresponding to a LVEF < 45%, documented by any accepted method within the previous 12 months. If documentation is not available within the required time frame, LVEF must be assessed prior to enrollment

    1. Worsening heart failure symptoms (current NYHA class III-IV). Patients must experience worsening of at least one of the symptoms described below at the time of entry into the study:
Dyspnea Symptoms:

  • Dyspnea (labored or difficult breathing) at rest

  • Worsening dyspnea (labored or difficult breathing) on minimal exertion

  • Worsening orthopnea (difficult breathing except in the upright position)

  • Increased frequency of nocturnal dyspnea (awaken from sleep due to respiratory distress)

  1. Clinical evidence of volume overload such as weight gain over previous few days, peripheral edema, hepatic congestion with ascites, pulmonary congestion, or pleural effusion

  1. Females of childbearing potential must have a negative pregnancy test at enrollment. A female is considered to be of childbearing potential unless she is post-menopausal (no menses for at least 12 consecutive months) or without a uterus and/or both ovaries

  2. Ability to understand and willing to sign Informed Consent Form

Exclusion Criteria:

  1. Incapable of taking the 6-minute walk test due to any condition unrelated to heart failure, e.g., muscular or skeletal disability

  2. Valvular heart disease requiring surgical intervention (during the course of the study. Patients with heart failure due to or associated with uncorrected primary valvular disease, malfunctioning artificial heart valve, or uncorrected congenital heart disease)

  3. History of or clinically significant evidence of any severe disease other than heart failure that preclude participation and complicate the evaluation of study results from the local laboratory:

  • Hepatic disease (AST, ALT, total bilirubin > 3 times Upper Limit of Normal (ULN), renal disease (S-Creatinine > 2.5 mg/dL),

  • Uncontrolled insulin-dependent diabetes mellitus with a history of frequent hypoglycemic episodes or frequent hospitalizations for hyperglycemia,

  • Cancer (excluding treated non-melanoma skin cancer)

  1. Unstable angina, cardiogenic shock, or acute pulmonary edema requiring any of the following: Nitroprusside, intravenous nitroglycerin, nesiritide, intravenous inotrope, or need for endotracheal intubation and mechanical ventilation

  2. Acute myocardial infarction and/or myocardial infarction within 30 days (prior to enrollment) as diagnosed by investigator's evaluation of clinical symptoms, ECG, and/or biochemical markers of cardiac injury

  3. Cardiac arrest (patients with history of cardiac arrest within 12 months unless precipitated by an event such as an acute myocardial infarction, induction by catheter placement, severe transient electrolyte abnormality, by an electrophysiology procedure, or addressed by Automatic Implantable Cardioverter Defibrillator placement. Patients with increased risk of cardiac arrest, QTc > 450 msec, atrial ventricular block II or III, etc.)

  4. Sustainable VT/VF within 30 days (> 15 seconds long; patients with enrollment ECG showing ventricular tachycardia or premature ventricular complexes associated with symptoms, or ventricular tachycardia of 6 beats)

  5. Uncontrolled atrial fibrillation on enrollment ECG with a ventricular rate >120 bpm

  6. Cardiac surgery within the last month or acutely required PCI (patients who have undergone a cardiac revascularization, valvular surgery, or biventricular resynchronization procedure within 30 days. Patients who have had ventricular reduction surgery or cardiac myoplasty and patients with mechanical ventricular assist device)

  7. Systolic blood pressure < 90 mmHg and > 200 mmHg

  8. Pulmonary embolism or DVT or history of pulmonary embolism or DVT within 6 months prior to enrollment

  9. Severe obstructive or restrictive pulmonary disease, patients with primary pulmonary hypertension and heart failure secondary to pulmonary disease, and severe pulmonary infection

  10. I.v. vasoactive treatment, e.g. vasodilators, positive inotropic agents, within 24 hours prior to enrollment (see details in Appendix E)

  11. Participation in another study evaluating an experimental treatment within the last 30 days which potentially could bias the outcome of this study

  12. Previous treatment with ZP120

  13. Patients known to abuse or actively abusing alcohol or illicit drugs. Abuse of alcohol is defined as the usual daily intake of more than 100 grams of ethanol per day, or more than approximately six 12-ounce bottles of beer, one 750 mL bottle of wine, or 250 mL of 80 proof spirits

  14. Inability or unwillingness to provide informed consent

  15. BMI outside range of 20-50 kg/m2 (BMI equal to 20 and 50 kg/m2 is accepted)

  16. Any other condition or therapy, which in the opinion of the Principal Investigator would make the patient unsuitable for this study

Contacts and Locations

Locations

Site City State Country Postal Code
1 LAC-USC Medical Center-Division of Cardiology Los Angeles California United States 90073
2 VA Medical Center -WLA Los Angeles California United States 90073
3 UCSD Medical Center San Diego California United States 92103-8411
4 San Francisco VA Medical Center San Francisco California United States 94121
5 University of CO Health Sciences Center Denver Colorado United States 123456
6 Health First Clinical Research Institute Melbourne Florida United States 32901
7 Univ. of Miami Miller School of Medicine, Jackson Memorial Medical Center Miami Florida United States 33136
8 Emory University Hospital/The Emory Clinic Atlanta Georgia United States 30322
9 Northside Hospital Atlanta Georgia United States 30342
10 Rush University Medical Center Chicago Illinois United States 60612
11 Community Hospital Anderson/Community Clinical Research Center Anderson Indiana United States 46011
12 University of Iowa Heart Failure Treatment Program Iowa City Iowa United States 52242
13 University of Maryland Baltimore Maryland United States 21201
14 Henry Ford Hospital Detroit Michigan United States 48202
15 Hennepin County Medical Center Minneapolis Minnesota United States 55415
16 The International Heart Institute Missoula Montana United States 59802
17 Bryan LGH Heart Institute Lincoln Nebraska United States 68510
18 University of Rochester Medical Center Rochester New York United States 14618
19 Cleveland Clinic Foundation Cleveland Ohio United States 44195
20 Lancaster Heart Foundation Lancaster Pennsylvania United States 17603
21 Albert Einstein Medical Center Philadelphia Pennsylvania United States 19141
22 Alamo Clinical Research Associates San Antonio Texas United States 78212

Sponsors and Collaborators

  • Zealand Pharma
  • Syneos Health

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00283361
Other Study ID Numbers:
  • 05-025
First Posted:
Jan 27, 2006
Last Update Posted:
Feb 28, 2007
Last Verified:
Feb 1, 2007
Additional relevant MeSH terms:
Heart Failure

Study Results

No Results Posted as of Feb 28, 2007